Alexander Hanzl

Alexander Hanzl

Auto-generated profile, based on publicly available information

Alexander Hanzl

Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 November 2022 in Nature Chemical Biology
Verified
Journal Article
Open access
PDF file
AHAlexander Hanzl
Alexander Hanzl
RCRyan Casement
Ryan Casement
HIHana Imrichova
Hana Imrichova
SHScott J. Hughes
Scott J. Hughes
EBEleonora Barone
Eleonora Barone
GWGeorg E. Winter
Georg E. Winter
Targeted protein degradation is a novel pharmacology established by drugs that recruit target proteins to E3 ubiquitin ligases. Based on the structure of the degrader and the target, different E3 interfaces are critically involved, thus forming defined ‘functional hotspots’. Understanding disruptive mutations in functional hotspots informs on the architecture of the assembly, and highlights residues susceptible to acquire resistance phenotypes. Here we employ haploid genetics to show that hotspot mutations cluster in substrate receptors of hijacked ligases, where mutation type and frequency correlate with gene essentiality. Intersection with deep mutational scanning revealed hotspots that are conserved or specific for chemically distinct degraders and targets. Biophysical and structural validation suggests that hotspot mutations frequently converge on altered ternary complex assembly. Moreover, we validated hotspots mutated in patients that relapse from degrader treatment. In sum, we present a fast and widely accessible methodology to characterize small-molecule degraders and associated resistance mechanisms.

5 January 2023 in Journal of the American Chemical Society
Verified
Journal Article
Open access
AHAlexander Hanzl
Alexander Hanzl
EBEleonora Barone
Eleonora Barone
SBSophie Bauer
Sophie Bauer
HYHong Yue
Hong Yue
RNRadosław P. Nowak
Radosław P. Nowak
GWGeorg E. Winter
Georg E. Winter
Targeted protein degradation (TPD) is a new pharmacology based on small-molecule degraders that induce proximity between a protein of interest (POI) and an E3 ubiquitin ligase. Of the approximately 600 E3s encoded in the human genome, only around 2% can be co-opted with degraders. This underrepresentation is caused by a paucity of discovery approaches to identify degraders for defined E3s. This hampers a rational expansion of the druggable proteome and stymies critical advancements in the field, such as tissue- and cell-specific degradation. Here, we focus on dynamic NEDD8 conjugation, a post-translational, regulatory circuit that controls the activity of 250 cullin RING E3 ligases (CRLs). Leveraging this regulatory layer enabled us to develop a scalable assay to identify compounds that alter the interactome of an E3 of interest by tracing their abundance after pharmacologically induced auto-degradation. Initial validation studies are performed for CRBN and VHL, but proteomics studies indicate broad applicability for many CRLs. Among amenable ligases, we select CRLDCAF15 for a proof-of-concept screen, leading to the identification of a novel DCAF15-dependent molecular glue degrader inducing the degradation of RBM23 and RBM39. Together, this strategy empowers the scalable identification of degraders specific to a ligase of interest.

10 April 2025 in ACS Central Science
Verified
Journal Article
Open access
PRPau Nadal Rodríguez
Pau Nadal Rodríguez
FHFrederick Hartung
Frederick Hartung
MPMarina Pedrola
Marina Pedrola
SCSeemon Coomar
Seemon Coomar
ADAlejandro Diaz-Moreno
Alejandro Diaz-Moreno
Ouldouz GhashghaeiOuldouz Ghashghaei
Ouldouz Ghashghaei
A multidisciplinary platform is presented to address aryl hydrocarbon receptor (AhR) modulation. A rewired Yonemitsu multicomponent reaction with indole 2-carboxaldehydes and nucleophilic species was designed to access a family of 6-substituted indolocarbazoles. The conformational behavior of these compounds was examined to rationalize their axial chirality. In silico docking and molecular simulations highlighted key features implicated in their binding to AhR. Furthermore, the synthesis of linkable derivatives allowed the direct development of conjugated entities. Reporter gene and target gene expression analyses identified these novel structures as potent noncytotoxic activating AhR ligands, that can be extended to bifunctional molecules. The anti-inflammatory properties of these AhR agonists were assessed in interleukin-13 treated keratinocytes. Altogether, the synergistic research in synthetic and computational chemistry integrated with biological studies opens novel avenues toward understanding the biological roles of AhR and the development of targeted therapeutics.

13 August 2026 in Nature Biotechnology
Verified
Journal Article
Open access
PDF file
PGPius Galli
Pius Galli
SXShuhao Xiao
Shuhao Xiao
YMYanxiang Meng
Yanxiang Meng
AHAlexander Hanzl
Alexander Hanzl
ABAlexandra M. Bendel
Alexandra M. Bendel
NTNicolas H. Thomä
Nicolas H. Thomä
Molecular glue degraders (MGDs), such as pomalidomide, induce degradation of non-native substrates by the cullin-RING E3 ligase 4 (CRL4) through its substrate receptor cereblon (CRBN). Here, to explore CRBN programmability, we tested whether reported CRBN–MGD substrates are part of a network of latent CRBN interactors, proteins capable of MGD-induced CRBN binding without detectable degradation. Leveraging a highly parallel protein complementation assay (GluePCA) to measure MGD-induced interaction between CRBN and zinc fingers, we identified ~210 zinc fingers bound to CRBN–pomalidomide, where top binders are already reported as degraded by dedicated MGDs. To map latent CRBN–MGD interactions proteome-wide and define the accessible CRBN interaction space, we combined artificial intelligence-derived protein surface queries (MaSIF-mimicry) with GluePCA. This pipeline identified 6 known and 43 novel CRBN–pomalidomide binders, including orthogonally validated hits. We find that these binders provide privileged starting points for MGD development. We expect this binding-focused workflow to be applicable to other MGD–E3 ligase systems, potentially extending the scope of this emerging drug class.